Jordan Berlin, MD
Medical Oncology · Nashville, TNNPI 1275620312
Payments from drug & device makers
Across 1,110 payments — averaging $3344.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Inc$1.1M
- Incyte Corporation$723K
- AbbVie$350K
- E.r. Squibb & Sons, L.L.C.$245K
- Pfizer$225K
- EMD Serono, Inc.$218K
- plus $840K from 27 others
Across 7 payments — averaging $1974.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$7K
- Bristol Myers Squibb$5K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Consulting fees$88,09074%
- Speaking & faculty fees$12,83811%
- Travel & lodging$15,68613%
- Food & beverage$1,5141%
- Education$1,6591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Inc | 359 | $1,110,554 |
| Incyte Corporation | 364 | $723,365 |
| AbbVie | 47 | $349,547 |
| E.r. Squibb & Sons, L.L.C. | 12 | $245,460 |
| Pfizer | 30 | $225,340 |
| EMD Serono, Inc. | 117 | $218,459 |
| Eli Lilly | 4 | $165,128 |
| Gilead | 4 | $125,103 |
| Genentech, Inc. | 8 | $117,792 |
| Taiho Oncology, Inc. | 12 | $105,520 |
| Bayer | 17 | $54,154 |
| Merck | 1 | $48,600 |
| Day One Biopharmaceuticals | 32 | $44,603 |
| Pharmacyclics LLC, An Abbvie Company | 18 | $29,950 |
| Ipsen Biopharmaceuticals, Inc | 25 | $29,218 |
| Array Biopharma Inc | 8 | $19,521 |
| Beigene AUS Pty Ltd | 4 | $16,594 |
| Merck Healthcare Kgaa | 4 | $16,004 |
| Karyopharm Therapeutics Inc. | 5 | $15,998 |
| EMD Serono Research & Development Institute, Inc. | 2 | $9,750 |
| Novocure Inc. | 7 | $6,921 |
| Novartis | 3 | $6,240 |
| Insmed, Inc. | 1 | $5,950 |
| Astrazeneca UK Limited | 4 | $4,864 |
| Regeneron | 5 | $4,473 |
| Boehringer Ingelheim International GmbH | 2 | $4,250 |
| Advanced Accelerator Applications | 3 | $2,291 |
| Beigene USA, Inc. | 2 | $1,650 |
| Immunomedics, Inc. | 1 | $1,645 |
| Mirati Therapeutics, Inc. | 3 | $1,560 |
| Clovis Oncology, Inc. | 2 | $1,554 |
| Bristol Myers Squibb | 3 | $698 |
| Exelixis Inc. | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,712,880 in reported general payments places this provider in the 90th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Nashville
- Melissa JohnsonNashville$46M
- David SpigelNashville$29.7M
- Howard BurrisNashville$12.2M
- Ingrid MayerNashville$6.3M
- Jennifer ChoeNashville$4.1M
- Cathy EngNashville$3.8M
- Kristen CiomborNashville$3.2M
- Vandana AbramsonNashville$3M
- Leora HornNashville$2.6M
- Robert RamirezNashville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.